Dorian Blake
Family · Englewood, CONPI 1396233490
Payments from drug & device makers
Across 219 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Lundbeck LLC$405
- Teva Pharmaceuticals USA, Inc.$249
- Scilex Pharmaceuticals Inc.$86
- Lilly USA, LLC$74
- plus $102 from 5 others
What the payments were for
- Consulting fees$84019%
- Food & beverage$3,61581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $2,157 |
| Pfizer | 44 | $1,382 |
| Lundbeck LLC | 26 | $405 |
| Teva Pharmaceuticals USA, Inc. | 19 | $249 |
| Scilex Pharmaceuticals Inc. | 5 | $86 |
| Lilly USA, LLC | 4 | $74 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Harmony Biosciences LLC | 1 | $22 |
| Bioventus LLC | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$975
How this compares
$4,455 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 79 | $62,149 |
| QuliptaAtogepant | 43 | $49,404 |
| Nurtec OdtRimegepant Sulfate | 39 | $41,647 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $20,519 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $11,071 |
| Diclofenac Potassium | 23 | $3,107 |
| Baclofen | 53 | $2,022 |
| Eletriptan HbrEletriptan Hydrobromide | 14 | $1,918 |
| Naratriptan Hcl | 60 | $1,849 |
| Sumatriptan Succinate | 43 | $1,778 |
| Gabapentin | 82 | $1,445 |
| RizatriptanRizatriptan Benzoate | 25 | $1,199 |
| Hydroxyzine Hcl | 42 | $762 |
| Verapamil ErVerapamil Hcl | 12 | $521 |
| Cyclobenzaprine Hcl | 28 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta | $2,157 | $49,40443 claims |
| PfizerNurtec Odt | $1,382 | $41,64739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Englewood
- Taylor CampbellEnglewood$16K
- Meagan MurgelEnglewood$11K
- Jennifer BurkeEnglewood$9K
- Brook KilianEnglewood$8K
- Annette WychgramEnglewood$8K
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.